[Federal Register Volume 83, Number 118 (Tuesday, June 19, 2018)]
[Notices]
[Pages 28446-28447]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13061]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical CBRN Defense Consortium

    Notice is hereby given that, on May 14, 2018, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. Sec.  4301 et seq. (``the Act''), Medical CBRN Defense 
Consortium (``MCDC'') has filed written notifications simultaneously 
with the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Spero Therapeutics, Inc., Cambridge, MA; DCN Diagnostics, 
Carlsbad, CA; Silver Lake Research

[[Page 28447]]

Corporation, Azusa, CA; Coagulant Therapeutics, Mill Valley, CA; Duke 
University, Durham, NC; International AIDS Vaccine Initiative (IAVI), 
New York, NY; AN2 Therapeutics, Inc., Menlo Park, CA; University of 
Nevada Reno, Reno, NV; New Mexico Institute of Mining and Technology, 
Socorro, NM; VecTOR Test Systems, Inc., Thousand Oaks, CA; The Regents 
of the University of California, Irvine, Irvine, CA; The Wistar 
Institute, Philadelphia, PA; Chenega Support Services, LLC, San 
Antonia, TX; PlantVax Inc., Rockville, MD; Binergy Scientific, Inc., 
Atlanta, GA; Zeteo Tech, Inc., Sykesville, MD; The Regents of 
University of New Mexico, Health Sciences Center, Albuquerque, NM; 
Rubicon Biotechnology, Lake Forest, CA; Innovative Emergency 
Management, Inc. (IEM), Arlington, VA; Macromoltek, Austin, TX; Paratek 
Pharmaceuticals, Boston, MA; Terminal Horizon Operations and 
Resourcing, Inc. (THOR), St. Petersburg, FL; Phosphorex Inc., 
Hopkinton, MA; Celina Tent, Inc., Celina, OH; Medinstill Development 
LLC, New Milford, CT; BioHybrid Solutions LLC, Pittsburgh, PA; 
GeneCapture Inc., Huntsville, AL; University of Arizona (Arizona Board 
of Regents), Tucson, AZ; Peregrine Technical Solutions, LLC, Yorktown, 
VA; and DxDiscovery, Inc., Reno, NV, have been added as parties to this 
venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MCDC intends to file additional 
written notifications disclosing all changes in membership.
    On November 13, 2015, MCDC filed its original notification pursuant 
to Section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to Section 6(b) of the Act on 
January 6, 2016 (81 FR 513).
    The last notification was filed with the Department on January 16, 
2018. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on February 27, 2018 (83 FR 8506).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2018-13061 Filed 6-18-18; 8:45 am]
 BILLING CODE 4410-11-P